The Society for Research on Nicotine and Tobacco and the Association for the Treatment of Tobacco Use and Dependence have developed a position statement recommending access to smoking cessation interventions for smokers in the high-risk group who undergo a lung cancer screen.
The Society for Research on Nicotine and Tobacco (SRNT) and the Association for the Treatment of Tobacco Use and Dependence (ATTUD) have developed a position statement recommending access to smoking cessation interventions for smokers in the high-risk group who undergo a lung cancer screen.
Published in Cancer, the authors conducted a literature review that supports the health benefits associated with smoking cessation in the high-risk group. According to the American Association for Thoracic Surgery, the high-risk group is defined by individuals 55 to 79-years old with a 30 pack-year history of smoking. In the current statement, SRNT and ATTUD provide clinical recommendations for integrating evidence-based smoking-cessation treatment with lung cancer screening.
In 2014, the US Preventive Services Task Force finalized a “B” recommendation for annual lung cancer screenings with low dose computed tomography (LDCT) for those identified as being at high-risk for developing lung cancer. Subsequently, in 2015, CMS announced a national coverage determination for LDCT screening as a preventive service benefit for these individuals if they received a written order from their healthcare provider.
“Lung screening with low dose CT will save many lives by detecting lung cancer at earlier, treatable stages,” said Benjamin A. Toll, PhD, associate professor of public health at the Medical University of South Carolina, in a statement. Toll is a co-author on the paper. “However, it is critical that we provide tobacco treatment in conjunction with lung screening. Most patients will not have lung cancer, and we do not want this to be perceived as a ‘free pass’ to smoke. We also wanted to highlight the multiple benefits of smoking cessation.”
Based on their review of evidence, the authors have suggested the following:
Toll believes, “Quitting smoking is the most important step patients can take to minimize risk for lung cancer and to also improve overall health. Combining smoking cessation with lung cancer screening will maximize the benefits of screening.”
Reference
Fucito LM, Czabafy S, Hendricks PS, Kotsen C, Richardson D, Toll BA. Pairing smoking-cessation services with lung cancer screening: a clinical guideline from the Association for the Treatment of Tobacco Use and Dependence and the Society for Research on Nicotine and Tobacco [published online February 2, 2016]. Cancer. 2016. doi: 10.1002/cncr.29926
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More